Axys Advanced Technologies Announces Combinatorial Chemistry Agreement with Cephalon.Business Editors/Health and Medical Writers SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--Dec. 23, 1999 Axys Pharmaceuticals, Inc. (Nasdaq:AXPH) today announced that Axys Advanced Technologies, Inc. (AAT Alpha-1-antitrypsin (AAT) A blood component that breaks down infection-fighting enzymes such as elastase. Mentioned in: Chronic Obstructive Lung Disease ), its combinatorial chemistry Combinatorial chemistry involves the rapid synthesis or the computer simulation of a large number of different but structurally related molecules. Introduction Synthesis of molecules in a combinatorial fashion can quickly lead to large numbers of molecules. subsidiary, entered into an agreement with Cephalon Ceph´a`lon n. 1. (Zool.) The head. , Inc. During the collaboration Axys Advanced Technologies will supply diverse compound screening libraries and chemistry services for use by Cephalon in their proprietary target based assays. Under the terms of the agreement AAT will receive payment from Cephalon for the delivery of compounds, as well as future payments if Cephalon utilizes AAT for chemistry support and services. "We are very excited to be working with Cephalon, our newest chemistry partner. AAT will provide at least 100,000 diverse compounds from 25 core scaffolds, and Cephalon will use its considerable screening capabilities to look at proprietary CNS See Continuous net settlement. CNS See continuous net settlement (CNS). based targets," commented Robert A. Reed, Ph.D., president at Axys Advanced Technologies. "This is our fourth agreement with a Biopharmaceutical company in less than a year, and fifth overall. Cephalon has advanced clinical and commercial programs and we are looking forward to working with them to add to their clinical pipeline." Dr. Jeffry L. Vaught, president of Research and Development at Cephalon, stated, "The AAT compounds will provide a broad array of diverse chemotypes, and will complement Cephalon's own medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. and optimization capabilities as well as its integrated target screening and drug discovery platform. Beyond the compound quality and diversity, we were particularly attracted to the potential of AAT's follow-up program. "As we continue to identify important molecular targets for neurology and oncology, the combination of immediate access to compounds along with the future flexibility offered through AAT provides us with a solid platform to successfully achieve our therapeutic objectives." Axys Advanced Technologies, Inc. (AAT), a subsidiary of Axys Pharmaceuticals, Inc., is a world leader in the design and production of innovative combinatorial chemistry. AAT expertise focuses on creating high quality, diverse compound libraries for HTS HTS Heights HTS Harmonized Tariff System HTS High Throughput Screening (biomolecular assay screening) HTS High-Throughput Screening (Pharmaceutical Industry) HTS Harmonized Tariff Schedule that yield novel chemotypes as hits. AAT offers fully validated chemistries that allow partners to rapidly progress their hits to lead compounds through a synergistic combination of combinatorial and medicinal chemistry techniques and strategies. AAT products include Enabled Compounds, Technology Transfer programs and Custom Chemistry Services. AAT partners include Pharmacia and Upjohn, Parke-Davis, Rhone-Poulenc Rorer, Daiichi Pharmaceuticals, Allergan, Signal Pharmaceuticals, Protein Design Labs, Novalon Pharmaceuticals and Elitra Pharmaceuticals. Axys Pharmaceuticals is a drug discovery and development company with a proprietary focus in oncology. Axys is building shareholder value through (1) a broad and diversified pipeline of research and development programs partnered with world-class pharmaceutical companies; (2) expansion of a non-partnered research and development franchise in oncology; and (3) the spin out of affiliated businesses that leverage the company's technologies in order to provide capital for Axys' drug discovery and development programs. Axys' technology-leveraging businesses are: Axys Advanced Technologies, a combinatorial chemistry oriented business; PPGx, a majority owned pharmacogenomics Pharmacogenomics is the branch of pharmacology which deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. company, and Akkadix, an agricultural biotechnology company. Cephalon, Inc., headquartered in West Chester West Chester, borough (1990 pop. 18,041), seat of Chester co., SE Pa., W of Philadelphia; inc. 1799. Primarily residential, West Chester was long the trade and processing center for an agricultural region that is now mainly suburbs. , Pa., is an international biopharmaceutical company dedicated to the discovery, development and marketing of products to treat neurological disorders This is a list of major and frequently observed neurological disorders (e.g. Alzheimer's disease), symptoms (e.g.back pain), signs (e.g. aphasia) and syndromes (e.g. Aicardi syndrome). , sleep disorders Sleep Disorders Definition Sleep disorders are a group of syndromes characterized by disturbance in the patient's amount of sleep, quality or timing of sleep, or in behaviors or physiological conditions associated with sleep. and cancer. For more information on Cephalon, please visit the company's Web site at www.cephalon.com. Except for the historical information contained herein, this press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties which could cause Axys' actual results to differ materially from those discussed here, including Axys' reliance on the efforts of its collaborative partners, the risk that Axys' collaborations will not be successful, the risk that clinical trials will not proceed as anticipated or may not be successful, the risk of Axys' early stage of development, the risk that Axys will not be successful in entering into new collaborations, competition and marketing risk, the risk of unexpected difficulties and delays in the development of new technologies and in expanding its manufacturing capabilities, and general economic conditions that may affect Axys' actual results and developments. Additional factors that could cause or contribute to such differences include, but are not limited to, those discussed in the sections entitled "What Factors Could Cause Our Results to Differ Significantly from Those You Might Expect?" and "Additional Risk Factors" in the company's SEC Reports, including the company's report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended Dec. 31, 1998. Note to Editors: For more information on Axys Pharmaceuticals, Inc., please visit the company's website at http://www.axyspharm.com. For more information on Axys Advanced Technologies, Inc. please visit the company's website at http://www.axystech.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion